Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism
β Scribed by U. Noring; U. Juul Povlsen; D. E. Casey; J. Gerlach
- Publisher
- Springer
- Year
- 1984
- Tongue
- English
- Weight
- 241 KB
- Volume
- 84
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
β¦ Synopsis
RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatment with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.
π SIMILAR VOLUMES
## Abstract Levodopa (Lβdopa) consistently primes basal ganglia for the appearance of dyskinesia in parkinsonian patients and 1βmethylβ4βphenylβ1,2,3,6βtetrahydropyridine hydrochloride (MPTP) βtreated primates. This finding may reflect its relatively short duration of effects resulting in pulsatile
Plasma MHPG levels and AMDP rating score were measured in depressed patients before treatment, and a follow-up study was performed during the next 3 months of drug therapy to detect possible relationships between the parameters. Before treatment, MHPG levels were moderately lower in depressed than i